Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics to Present at the Biotech Showcase(TM) 2016 Conference

PR Newswire January 6, 2016

Timing is Crucial, Upside Analysis - Analyst Notes on Mercury Systems, Synthetic Biologics, CRA International and Altisource Asset Management

Accesswire December 15, 2015

Promising Clinical Trials Coming in 2016 for IBD, Prostate Cancer and Spinal Cord Injuries

Accesswire December 15, 2015

Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire December 8, 2015

Synthetic Biologics to Webcast Microbiome Clinical Program Seminar

PR Newswire December 7, 2015

Synthetic Biologics Announces Positive Topline Results from First Phase 2a Clinical Trial of SYN-004, the Company's Candidate for the Prevention of C. difficile Infection

PR Newswire December 1, 2015

Synthetic Biologics Reports that Data from the Phase 2 Trimesta(TM) Clinical Trial for Relapsing-Remitting Multiple Sclerosis were Published by Lead Principal Investigator

PR Newswire November 25, 2015

Synthetic Biologics Announces Issuance of First Key U.S. Patent Directly Covering SYN-010, the Company's Novel Candidate for Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire November 24, 2015

A Look Inside the Chart, Technical Insights - Research on Tilly's, Geospace Technologies, Synthetic Biologics and TrovaGene

Accesswire November 20, 2015

Synthetic Biologics to Host Microbiome Clinical Program Seminar in New York City

PR Newswire November 19, 2015

Synthetic Biologics Reports Third Quarter 2015 Financial Results and Operational Highlights

PR Newswire November 5, 2015

Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough (Pertussis)

PR Newswire October 21, 2015

Synthetic Biologics' Novel Irritable Bowel Syndrome with Constipation (IBS-C) Program Featured in American College of Gastroenterology Poster

PR Newswire October 20, 2015

Synthetic Biologics to Report Third Quarter Results on November 5, 2015

PR Newswire October 19, 2015

Synthetic Biologics Initiates Second SYN-010 Phase 2 Clinical Trial Intended to Treat Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire October 8, 2015

Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing

PR Newswire October 1, 2015

Synthetic Biologics Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial

PR Newswire September 28, 2015

Synthetic Biologics Reports First Analysis Demonstrating SYN-004's Ability to Protect the Microbiome from Damage Caused by IV Antibiotics in a Humanized Pig Model

PR Newswire September 21, 2015

Synthetic Biologics Reports Second Quarter 2015 Financial Results and Operational Highlights

PR Newswire August 10, 2015

Intrexon and Synthetic Biologics Enter ECC to Develop Novel Biotherapeutics for Treatment of Phenylketonuria

PR Newswire August 10, 2015